Monocast 4 mg Oral Granules can be administered directly into the mouth, or mixed with a spoonful of soft food (e.g., applesauce, mashed carrots, rice, or ice cream) at room temperature. The granules should not be dissolved in liquid. Do not open the sachet until ready to use. Administer within 15 minutes of opening the sachet. Do not store for future use. It is usually taken once daily in the evening for asthma and perennial allergic rhinitis, or at a time convenient for seasonal allergic rhinitis.

Montelukast selectively blocks the cysteinyl leukotriene type 1 (CysLT1) receptor. Leukotrienes are inflammatory mediators released from cells such as mast cells and eosinophils, contributing to bronchoconstriction, mucus secretion, vascular permeability, and eosinophil recruitment in the airways. By blocking these receptors, Montelukast inhibits the actions of leukotrienes, leading to reduced airway inflammation, improved lung function, and alleviation of allergic rhinitis symptoms.

• •Hypersensitivity to Montelukast or any component of the formulation.
• •Monocast is not indicated for use in the reversal of bronchospasm in acute asthma attacks.

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children. Do not open the sachet until ready to use.

In most overdose reports, no adverse events were reported. The most common adverse events were thirst, somnolence, mydriasis, hyperkinesia, and abdominal pain. Treatment is symptomatic and supportive.

Pregnancy Category B. Studies in animals have not shown harm to the fetus. There are no adequate and well-controlled studies in pregnant women. Use only if clearly needed. Montelukast is excreted into breast milk. Caution should be exercised when administered to a nursing mother.